1. Home
  2. CISS vs GOVX Comparison

CISS vs GOVX Comparison

Compare CISS & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C3is Inc.

CISS

C3is Inc.

N/A

Current Price

$1.16

Market Cap

2.7M

ML Signal

N/A

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

N/A

Current Price

$1.85

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CISS
GOVX
Founded
2022
2001
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7M
3.0M
IPO Year
2022
1996

Fundamental Metrics

Financial Performance
Metric
CISS
GOVX
Price
$1.16
$1.85
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $240.00
AVG Volume (30 Days)
★ 371.3K
286.6K
Earning Date
11-18-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $2,489,145.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.82
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.06
$0.11
52 Week High
$6.06
$1,002.75

Technical Indicators

Market Signals
Indicator
CISS
GOVX
Relative Strength Index (RSI) 53.06 55.16
Support Level $0.26 $0.11
Resistance Level $1.76 $3.00
Average True Range (ATR) 0.26 0.31
MACD 0.04 0.30
Stochastic Oscillator 42.27 62.62

Price Performance

Historical Comparison
CISS
GOVX

About CISS C3is Inc.

C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including national and private industrial users, commodity producers, and traders. The company owns and operates a fleet of two dry bulk carriers that transport bulk commodities such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

Share on Social Networks: